<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ FAB.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">FAB.L</div>
            <div class="company-name">Fusion Antibodies plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£17,048,437</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 618 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ WATCH</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">49</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">40</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fef3c7; color: #92400e;">EARLY BUILD</span>
            </div>
            
            <div class="thesis-line">
                WATCH - EARLY_BUILD timing with 49/100 opportunity score
            </div>
        </div>

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 49/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: EARLY_BUILD</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 2 rallies, 488% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 40/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 8/20 ‚Ä¢ Score: 10/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 92.7% from peak ‚Ä¢ Score: 19/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Normal volume</strong><br><small>1.4x average ‚Ä¢ Score: 3/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>2 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Major upside</strong><br><small>Historical best: +488% ‚Ä¢ Score: 12/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">358%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">488%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">0.7x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Early stage positioning offers best R:R if catalysts appear</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">timing=EARLY BUILD ‚Ä¢ current return=358.0%</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Triangulation not loaded (RNS/social/trends missing)</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">HISTORICAL ONLY ‚Ä¢ confidence capped at 65</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Watch / Starter</div>
                    <div style="font-size: 14px; opacity: 0.9;">Wait for base + catalyst confirmation; starter position only</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0-1% until CONFIRMED</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Invalidation = breaks recent lows / dilution / suspension</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out 25% at +15%, 25% at +50%, runner above</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 49/100 APEX score. Historical data shows 2 rallies averaging 488% upside. Current position: +358.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Early regime often offers best risk/reward</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Early accumulation phase. Watch for confirmation before committing size.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 40/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Update on negotiations with NCI regarding OptiMAL</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Update on negotiations with NCI regarding OptiMAL | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">19th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Update on negotiations with NCI regarding OptiMAL</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìà IMPROVING: Company demonstrating strength and growth</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
19 Dec 2025 07:00
RNS Number : 1835M
Fusion Antibodies PLC
19 December 2025
19 December 2025
Fusion Antibodies plc
("Fusion"
or the
"Company")
Update on negotiations with NCI regarding OptiMAL¬Æ
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the National Cancer Institute ("
NCI
") between November 2023 and earlier this year, the NCI has expressed an interest in continuing to use OptiMAL¬Æ as a frontline human antibody discovery platform for a range of targets. Consequently, the NCI has provided Fusion with a proposal to extend the collaboration agreement entered in November 2023 (the "
Agreement
") to allow screening of several named targets.
Having reviewed the initial proposal for an extension to the Agreement, Richard Buick, CSO, and Adrian Kinkaid, CEO, met with Mitchell Ho of the NCI at the recent Antibody Engineering and Therapeutics conference in San Diego. The discussions included options to extend the NCI's use of OptiMAL¬Æ and various administrative pathways to achieve this. The immediate needs of NCI are to support current and imminent screening projects using OptiMAL¬Æ. The latest discussions also encompassed possible additional projects with enhanced ownership for Fusion Antibodies.
Negotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCI is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.
Adrian Kinkaid, Chief Executive Officer of Fusion Antibodies, commented:
"The NCI's interest in continuing to use OptiMAL¬Æ is a strong validation of the platform following the initial programme. We are encouraged by the constructive discussions around extending the collaboration and supporting additional targets, while recognising that formal approval processes are still ongoing."
Further updates will be provided in due course.
Enquiries:
Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub
Investor hub
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
Fusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here,
https://investorhub.fusionantibodies.com/s/1b6535
.
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody discovery including using the proprietary OptiMAL¬Æ platform, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx¬†TM¬†platform and¬†the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 290 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCFZMMZVRRGKZM
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Update on negotiations with NCI regarding OptiMAL</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Update on negotiations with NCI regarding OptiMAL | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">19th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Update on negotiations with NCI regarding OptiMAL</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìà IMPROVING: Company demonstrating strength and growth</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
19 Dec 2025 07:00
RNS Number : 1835M
Fusion Antibodies PLC
19 December 2025
19 December 2025
Fusion Antibodies plc
("Fusion"
or the
"Company")
Update on negotiations with NCI regarding OptiMAL¬Æ
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the National Cancer Institute ("
NCI
") between November 2023 and earlier this year, the NCI has expressed an interest in continuing to use OptiMAL¬Æ as a frontline human antibody discovery platform for a range of targets. Consequently, the NCI has provided Fusion with a proposal to extend the collaboration agreement entered in November 2023 (the "
Agreement
") to allow screening of several named targets.
Having reviewed the initial proposal for an extension to the Agreement, Richard Buick, CSO, and Adrian Kinkaid, CEO, met with Mitchell Ho of the NCI at the recent Antibody Engineering and Therapeutics conference in San Diego. The discussions included options to extend the NCI's use of OptiMAL¬Æ and various administrative pathways to achieve this. The immediate needs of NCI are to support current and imminent screening projects using OptiMAL¬Æ. The latest discussions also encompassed possible additional projects with enhanced ownership for Fusion Antibodies.
Negotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCI is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.
Adrian Kinkaid, Chief Executive Officer of Fusion Antibodies, commented:
"The NCI's interest in continuing to use OptiMAL¬Æ is a strong validation of the platform following the initial programme. We are encouraged by the constructive discussions around extending the collaboration and supporting additional targets, while recognising that formal approval processes are still ongoing."
Further updates will be provided in due course.
Enquiries:
Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub
Investor hub
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
Fusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here,
https://investorhub.fusionantibodies.com/s/1b6535
.
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody discovery including using the proprietary OptiMAL¬Æ platform, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx¬†TM¬†platform and¬†the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 290 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCFZMMZVRRGKZM
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Launch of OptiMAL platform</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Launch of OptiMAL platform | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">16th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">11:04 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Launch of OptiMAL platform</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìà IMPROVING: Company demonstrating strength and growth</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
16 Dec 2025 11:04
RNS Number : 7820L
Fusion Antibodies PLC
16 December 2025
16 December 2025
Fusion Antibodies plc
("Fusion"
or the
"Company")
Launch of the OptiMAL¬Æ Human Antibody Discovery platform
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the official launch of the OptiMAL¬Æ platform for the discovery of novel human antibodies. The OptiMAL¬Æ platform incorporates the Company's na√Øve, synthetic library of antibody sequences and the Mammalian Display used to select individual antibodies from the Library against a target of interest. As has been previously announced by the Company, the OptiMAL¬Æ library and the method for designing the Library are protected under US patent no. US12378696 and patents pending in other territories.
The official launch of the OptiMAL¬Æ platform took place at the Antibody Engineering and Therapeutics conference in San Diego with a speaker presentation by Dr. Richard Buick, CSO, followed by poster presentations and an exhibit booth. CEO Adrian Kinkaid also attended the official launch of OptiMAL¬Æ.
Richard Buick, CSO of Fusion, said
:
"I am delighted to see the culmination of several years' work presented to an audience of antibody industry peers and look forward to the future of using this technology to bring more human therapeutic antibodies to the market."
Enquiries:
Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub
Investor hub
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx¬†TM¬†platform and¬†the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCFFEFFMEISESE
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Mammalian Display video</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 55/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Mammalian Display video | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">11th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS-R</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">55/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Mammalian Display video</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Integration Efficiency</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">70%, 70%, 5%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
11 Dec 2025 07:00
RNS Number : 0994L
Fusion Antibodies PLC
11 December 2025
REACH - Non-regulatory announcement*
11 December 2025
Fusion Antibodies plc
("Fusion"
or the
"Company")
Mammalian Display
video
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL¬Æ Human Antibody Discovery platform at the Antibody Engineering and Technology conference in San Diego on 15 December 2025, Fusion has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Mammalian Display technology. The technology has been combined with Fusion's Opti-library to create the OptiMAL¬Æ library. OptiMAL¬Æ is intended to be used to discover novel human antibodies against any target. The mammalian display platform library design and method is protected by US patent US12378696. The Mammalian Display technology can also be used with other antibody libraries.
The video can be viewed on the Investor Hub section of Fusion's website at,
https://investorhub.fusionantibodies.com/s/7ea305
.
Other Mammalian Display technologies are available and have been summarised in the scientific literature e.g. Slavny P, Hegde M, Doerner A, Parthiban K, McCafferty J, Zielonka S and Hoet R (2024) Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects. Front. Immunol. 15:1469329. doi: 10.3389/fimmu.2024.1469329.
Fusion Antibodies has compared its own Mammalian Display technology to the competitor platforms in the review article and identified several superior advantages. The most significant are its transduction efficiency of over 70% and its ability to support very large libraries, exceeding 10‚Åπ variants. These are summarised in the table below:
Technology
OptiMAL¬Æ
Retrocyte Display
Other Lentiviral mammalian display
Transposase-mediated integration
Nuclease-directed integration
Recombinase-mediated integration
Integration Efficiency
>70%
<5%
0.5-5%
6-7.5%
0.5-5%
1.7%
Reported library sizes
>109
106-108
106
106
106-108
106-108
If shareholders or prospective investors have further queries regarding the Mammalian Display platform, please submit questions you may have regarding this update using the facility provided.
Investor Presentation and Q&A: OptiMAL¬Æ Launch
Adrian Kinkaid, CEO of Fusion will provide a pre-recorded presentation and Q&A session on the OptiMAL¬Æ¬†launch¬†from the Antibody Engineering & Therapeutics Conference via the Company's Investor Hub on Tuesday, 16 December 2025, at 16:00 GMT.
The presentation is open to all existing and potential shareholders. Questions are encouraged and can be pre-submitted via the webinar page.
Register and submit your questions here:
https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a
No material new information will be included in the presentation or Q&A.
Fusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here,
https://investorhub.fusionantibodies.com/s/1b6535
.
Enquiries:
Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub
Investor hub
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx¬†TM¬†platform and¬†the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
*About Reach announcements
This is a Reach announcement. Reach is an¬†investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to¬†distribute¬†media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
NRATMBBTMTJBTAA
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Holding(s) in Company</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 100/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    HOLDING DISCLOSURE: Holding disclosed | üìä NEUTRAL: Significant holder at 7.1188% - potential price setter or activist.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">24th Mar 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4:38 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">100/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">HOLDING DISCLOSURE: Holding disclosed</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä NEUTRAL: Significant holder at 7.1188% - potential price setter or activist.</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìä ANALYZE: Determine offer price, arbitrage opportunity if discount</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">7.118800%, 7.107200%, 0.011600%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
24 Mar 2025 16:38
RNS Number : 9361B
Fusion Antibodies PLC
24 March 2025
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BDQZGK16
Issuer Name
FUSION ANTIBODIES PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Rathbones Investment Management Ltd
City of registered office (if applicable)
London
Country of registered office (if applicable)
United Kingdom
Name
City of registered office
Country of registered office
Investec Wealth & Investment Limited
London
United Kingdom
4. Details of the shareholder
Name
City of registered office
Country of registered office
Hero Nominees Limited
St Peter Port
Guernsey
Ferlim Nominees Limited
London
United Kingdom
Rathbone Nominees Limited
London
United Kingdom
5. Date on which the threshold was crossed or reached
21-Mar-2025
6. Date on which Issuer notified
24-Mar-2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
7.118800
0.000000
7.118800
7467753
Position of previous notification (if applicable)
4.732400
0.000000
4.732400
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible)
Number of direct voting rights (DTR5.1)
Number of indirect voting rights (DTR5.2.1)
% of direct voting rights (DTR5.1)
% of indirect voting rights (DTR5.2.1)
GB00BDQZGK16
7467753
7.118800
Sub Total 8.A
7467753
7.118800%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument
Expiration date
Exercise/conversion period
Number of voting rights that may be acquired if the instrument is exercised/converted
% of voting rights
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument
Expiration date
Exercise/conversion period
Physical or cash settlement
Number of voting rights
% of voting rights
Sub Total 8.B2
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling person
Name of controlled undertaking
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
Rathbones Group Plc
Rathbones Investment Management Limited
7.107200
7.107200%
Rathbones Group Plc
Investec Wealth & Investment Limited
0.011600
0.011600%
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
None
12. Date of Completion
24-Mar-2025
13. Place Of Completion
Port of Liverpool Building, Liverpool L3 1NW
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
HOLPPUQWWUPAGQC
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-12 ‚Ä¢ CrashDash APEX Engine<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
        </div>

    </div>
</body>
</html>